The global liver cancer treatment market is anticipated to grow at a CAGR of 10.2% during the forecast period (2021-2027). The rising change in lifestyle of people such as consumption of alcohol, rising prevalence of liver cancer cases, increasing awareness for the treatment of cancer, and rising FDA approvals, are driving the liver cancer treatment market during the forecast period. For instance, according to the WHO data, globally, in 2020, there were around 905,677 (4.7%) new liver cancer cases and 830,180 (8.3%) deaths due to liver cancer.
Browse the full report description of "Global Liver Cancer Treatment Market Size, Share & Trends Analysis Report by Treatment (Liver Cancer Surgery, Tumor Ablation, Embolization Therapy, Radiation Therapy, Targeted Therapy, Immunotherapy, and Chemotherapy), By End-User (Hospitals & Clinics, and Research Centers) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/liver-cancer-treatment-market
In March 2020, the US Food and Drug Administration (FDA) has approved Bristol Myers Squibb's liver cancer drug combination. Patients with hepatocellular carcinoma (HCC), one of the most aggressive and widespread forms of liver cancer, will receive the Opdivo (nivolumab) plus Yervoy (ipilimumab) drug treatment. Apart from it, in March 2020, Dicerna Pharmaceuticals, Inc., a developer of investigational ribonucleic acid interference (RNAi) therapeutics, has announced that it has received the US FDA approval for orphan drug designation (ODD) to Dicerna's DCR-A1AT for the treatment of alpha-1 antitrypsin (A1AT) deficiency. A1AT deficiency is a hereditary condition that can lead to lung and liver disease. Children with the disease's liver manifestations may experience jaundice (yellowing of the skin and whites of the eyes) and scar tissue formation in the liver (cirrhosis). Adults with liver disease can develop cirrhosis, progress to liver failure, or develop hepatocellular carcinoma, a form of liver cancer.
Furthermore, in December 2018, AVEO Oncology has announced a partnership with AstraZeneca to evaluate the efficacy of the company’s drugs. In a Phase 1/2 trial, AstraZeneca's IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1), was used in conjunction with AVEO's FOTIVDA(tivozanib), an oral, and highly-selective vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) in first-line hepatocellular carcinoma (HCC), or liver cancer. However, the demand for the treatment of cancers, new drugs, FDA approvals, and device launches, and the increasing prevalence of cancer patients could impede the global liver cancer diagnosis and treatment market over the coming years.
Market Coverage
o By Treatment
o By End-User
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Liver Cancer Treatment Market Report Segment
By Treatment
By End-User
Global Liver Cancer Treatment Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/liver-cancer-treatment-market